

SENATE APPROPRIATIONS COMMITTEE FISCAL NOTE

BILL NO. House Bill 1662

PRINTER NO. 4050

AMOUNT

\$216,000

FUND

General Fund

DATE INTRODUCED

June 19, 2019

PRIME SPONSOR

Representative Tomlinson

DESCRIPTION

House Bill 1662 amends the Methadone Death and Incident Review Act to include deaths and incidents attributable to any medication approved for the treatment of opioid use disorder and renames the act to the Medication Death and Incident Review Act.

The legislation expands the Methadone Death and Incident Review Team (MDAIR Team) established by the Department of Drug and Alcohol Programs (department) to include the following individuals:

- A representative from a recovery organization;
- An office-based agonist treatment provider who is assigned a waiver from the Drug Enforcement Administration to provide office-based prescribing of buprenorphine;
- A representative of the Department of Health who is affiliated with the Achieving Better Care by Monitoring All Prescriptions Program (ABC-MAP); and
- A toxicologist.

House Bill 1662 expands the duties of the MDAIR Team to include a review of all deaths and incidents from any medication approved by the United States Food and Drug Administration for the treatment of opioid use disorder.

The act shall take effect in 90 days.

FISCAL IMPACT:

The changes to the MDAIR Team contained in House Bill 1662 will require the hiring of two additional staff at the department to accommodate the new cases that will be referred as a result of adding other medications used in the treatment of opioid use disorder as outlined in the legislation. The department's General Government Operations for FY 2019-20 was \$2,657,000. According to the department, the estimated cost for two new program staff is \$216,000 on an annualized basis.